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€9575/LY and €8714/QALY. CONCLUSIONS: The use of pegin-
terferon alfa-2a (40KD) in CHB patients, as compared with
current practice, has the potential of improving clinical outcomes
with a cost per LY and QALY gained below that of universally
accepted therapies.
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OBJECTIVE: To estimate the cost-effectiveness of oseltamivir in
the treatment of inﬂuenza in three different population groups
in Finland: Otherwise Healthy Adults aged 13-65 years (OHA);
Children aged 1-12 years (C); At-Risk Patients including elderly
≥65 years (ARP). METHODS: The cost-effectiveness of
oseltamivir vs symptomatic relief was compared using a deci-
sion–analytic model. Analyses were made both from the health-
care payer and the societal perspective. Health Outcomes
determined were days of normal activity and quality-adjusted life
years (QALY) gained. A life-time horizon was used to take
account of life-years lost due to mortality. Probabilities, utilities
and resource use data in the model were derived from published
Finnish population level trials and registers, from oseltamivir
clinical trials and from other published literature. A discount rate
of 5 % was applied. Unit costs were obtained from the 2001
Finnish Guidelines for Health Care Unit Cost converted to a
2005 level. Probabilistic Sensitivity Analysis was used to explore
the uncertainty around the base case means. RESULTS: The
mean cost from a health care payer perspective per day of normal
activity and per QALY gained respectively for the 3 different
population groups were: OHA €27/€12,008; C €14/€15,469;
ARP €7/€685. In OHA, oseltamivir is cost-saving when loss of
productivity is taken into account. CONCLUSION: The analy-
ses demonstrate that, in comparison with usual care, cost per
QALY gained with oseltamivir is below internationally accepted
thresholds. Oseltamivir is a cost-effective treatment for inﬂuenza
in all population groups (particularly in the ARP group) and is
cost-saving from a societal perspective in OHA. 
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OBJECTIVES: To assess the clinical effectiveness and costs of
teicoplanin or vancomycin use in acute hospital infections treat-
ment from service-provider perspective in Poland. METHODS:
Results of a systematic review of published clinical trials selected
in accordance with Cochrane Collaboration criteria were used
to assess effectiveness and safety. Systematic review was con-
ducted in April 2006; Medline (Pubmed) Cochrane and
EMBASE were searched. Only RCTs with credibility assessment
of 2 or more points according to Jadad scale were included in
the systematic review; relevant clinical data were pooled with
RevMan 4.2. Overall costs of treatment were taken into account;
pharmacotherapy and drug administration, drug monitoring,
patient monitoring and adverse events inﬂuenced the total cost
of treatment. CMA was used to assess savings from service-
provider perspective in case of cheaper drug use in clinical prac-
tice. Sensitivity analysis was made according to range of costs of
vancomycin generics available in Poland and number of days of
therapy. All calculations were performed for 2006 (1Euro =
3.8PLN). RESULTS: Nineteen relevant clinical trials with direct
comparison of teicoplanin and vancomycin were found. Clinical
effects of the drugs were similar and no signiﬁcant differences in
effectiveness were found in pooled data from RCTs. Teicoplanin
treatment was associated with higher costs of drug acquisition
compared to vancomycin (difference: 337PLN (€88.7) but Tar-
gocid occurred much cheaper referring to: drug level monitor-
ing, patient monitoring and administration costs. So, overall
treatment with teicoplanin occurred cheaper than vancomycin;
savings from service-provider perspective were: 743.3PLN
(€195.6) per therapy. CONCLUSIONS: Targocid treatment lead
to signiﬁcant savings for service-providers in average acute 
hospital infections treatment in Poland in comparison to 
vancomycin.
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OBJECTIVES: Comparative evaluation of two options for the
treatment of acute hepatitis C: immediate monotherapy of all
patients with (pegylated) interferon versus delayed combination
therapy of patients who do not experience spontaneous viral
clearance within three months after diagnosis with interferon
and ribavirin, and also a comparison between the applied
monotherapies for the immediate treatment option. METHODS:
Economic evaluation is based on three prospective nonrandom-
ized outcome studies. In two monotherapy studies (n = 128)
patients were treated with 5 million units of Interferon alfa-2b
daily during the ﬁrst 4 weeks and three times a week during the
following 20 weeks or with 1.5 μg/kg pegylated Interferon alfa-
2b weekly over a period of 24 weeks. In the combination therapy
study different dosages of interferon and ribavirin were admin-
istered. The evaluation focused on direct medical costs and
included physican’s fees, laboratory, as well as medication costs,
taking a societal perspective. Partial indirect costs were raised ex
post by enquiry of participants and physicians. Costs were
valued at 2002 market-prices. RESULTS: Monotherapy and
combination therapy of hepatitis C showed a similar high efﬁ-
cacy (sustained response rate: 87% vs. 90%). Patients in delayed
combination therapy study showed a quite high rate of sponta-
neous viral clearance of almost 50%. Direct medical costs of
immediate therapy (€7064/patient) were €321 lower than those
of delayed therapy (p = 0.8). Pegylated compared with unpegy-
lated interferon yielded €511 additional costs per patient (p =
0.01) in monotherapies. Considering the current genotype-
dependent therapy standard and the observed rate of sustained
responders, average costs per patient amounted to €10,848 and
were about 50% higher than costs of the immediate monother-
apy. Sensitivity analysis indicated a robust model. CONCLU-
SIONS: As there are no signiﬁcant differences in treatment
efﬁcacy, monotherapy seems to be slightly more cost-effective.
Medication is responsible for more than 90% of direct costs.
